CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1 Study of HMBD-002-V4C26 (HMBD-002), a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05082610
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:11.834792+00:00
Published At: 2025-10-16T00:00:00+00:00
Record Updated At: 2025-10-16
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Cancer", "Tumor, Solid", "Nonsmall Cell Lung Cancer", "Triple Negative Breast Cancer", "Malignant Neoplasm", "Metastatic Cancer", "Advanced Solid Tumor"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-10-16"
protocolSection.identificationModule.nctId: "NCT05082610"
protocolSection.identificationModule.officialTitle: "A Phase 1 Study of HMBD-002-V4C26 (HMBD-002), a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Malignancies"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.